Whitehawk Therapeutics, Inc.

Listed Company

WHWKCIK 0001422142NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$7.14M

Net Income

$-20.60M

Total Assets

$150.83M

Equity

$136.31M

Shares Out

49.45M

Op. Cash Flow

$-97.43M

WHWK$3.90+109.68% · past yearDBEQ Basic

Daily closing prices

Business

Whitehawk Therapeutics is a clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens using an advanced CPT113 linker-payload platform. The company's lead candidates—HWK-007 (PTK7-directed), HWK-016 (MUC16-directed), and HWK-206 (SEZ6-directed biparatopic)—are in Phase 1 clinical trials for solid tumors including lung, ovarian, endometrial, and small-cell lung cancers. The company operates virtually with outsourced development and manufacturing through partnerships with WuXi Biologics and Hangzhou DAC, and divested its legacy FYARRO product business in March 2025.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	7	26	24	15	14
Selling, general and administrative	30	37	45	40	19
Research and development	91	51	49	33	20
Restructuring charges	0	3	0	—	—
Cost of goods sold	760,000	3	3	1	0
Total operating expenses	122	93	96	78	112
Loss from operations	−114	−67	−72	−63	−111
Gain on sale of business	87	0	—	—	—
Foreign exchange gain (loss)	5,000	−4,000	−1,000	0	—
Other income	302,000	0	—	—	—
Interest income	6	4	6	2	13,000
Interest expense	0	−154,000	−231,000	—	—
Total other income (expense), net	94	4	6	2	1
Loss before income tax expense	−21	−64	−66	−61	−110
Income tax expense	0	0	0	0	−2,000
Net loss	−21	−64	−66	−61	−110
Unrealized gain (loss) on investments, net of tax	104,000	−11,000	—	—	—
Comprehensive loss	−20	−64	−66	−61	−111
Net loss per share, basic (in dollars per share)	−0.33	−2.36	−2.44	−2.69	−12.41
Net loss per share, diluted (in dollars per share)	−0.33	−2.36	−2.44	−2.69	−12.41
Weighted average number of common shares outstanding, basic (in shares)	62	27	27	23	9
Weighted average number of common shares outstanding, diluted (in shares)	62	27	27	23	9

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	38	29	63	39	149
Short-term investments	108	19	46	134	0
Accounts receivable, net	0	6	5	2	0
Inventory	0	5	6	2	0
Prepaid expenses and other current assets	3	3	4	4	2
Total current assets	149	61	125	180	151
Property and equipment, net	3,000	7	5	508,000	57,000
Operating lease right-of-use assets	0	787,000	1	2	557,000
Other assets	2	1	2	2	2
Total assets	151	70	132	184	158
Accounts payable	917,000	2	6	4	6
Accrued liabilities	14	15	14	15	9
Operating lease liabilities, current portion	0	268,000	434,000	394,000	131,000
Total current liabilities	15	17	26	19	15
Operating lease liabilities, net of current portion	0	565,000	833,000	1	474,000
Other liabilities	0	202,000	0	—	—
Total liabilities	15	18	27	26	22
Commitments and contingencies (Note 13)	—	—	—	—	—
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.0001 par value, 300,000,000 shares authorized; 47,145,719 and 24,680,708 shares issued and outstanding as of December 31, 2025 and 2024 respectively	4,000	2,000	2,000	2,000	2,000
Additional paid-in capital	489	385	374	362	279
Accumulated other comprehensive income	120,000	16,000	27,000	−115,000	0
Accumulated deficit	−353	−333	−269	−203	−143
Total stockholders equity	136	52	105	158	136
Total liabilities and stockholders equity	151	70	132	184	158

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation expense	10	11	12	10	2
Amortization of premiums and discounts on short-term investments, net	−2	−1	−3	—	—
Non-cash lease expense	74,000	460,000	461,000	382,000	171,000
Depreciation and amortization expense	79,000	193,000	169,000	159,000	105,000
Accounts receivable	−1	−415,000	−4	−2	14
Inventory	170,000	1	−3	−2	0
Prepaid expenses and other current assets	−434,000	3	4	−1	−2
Other non-current assets	−438,000	518,000	518,000	437,000	481,000
Operating lease liabilities, net	−89,000	−512,000	−502,000	−291,000	−129,000
Accounts payable and accrued liabilities	4	−10	−132,000	3	8
Other liabilities	−202,000	202,000	0	0	−8
Net cash used in operating activities	−97	−60	−60	−50	−22
Proceeds from sale of business, net cash, cash equivalents, and restricted cash	101	0	—	—	—
Purchases of property and equipment	−552,000	−2	−4	−444,000	−46,000
Purchases of short-term investments	−149	−36	−64	−145	—
Maturities of short-term investments	60	63	152	13	0
Net cash provided by investing activities	12	25	83	−133	25
Proceeds from sale of common stock and prefunded warrants in PIPE financing	100	0	0	73	0
Payment of PIPE financing related transaction costs	−6	0	0	−322,000	−10
Issuance of common stock upon exercise of stock options	26,000	0	78,000	401,000	833,000
Proceeds from issuance under employee stock purchase plan	49,000	146,000	408,000	323,000	0
Deferred offering costs paid for financing	−76,000	−16,000	−160,000	−337,000	0
Net cash provided by financing activities	94	130,000	326,000	73	142
Net increase (decrease) in cash, cash equivalents and restricted cash	9	−34	24	−110	145
Interest paid during the period	0	211,000	230,000	230,000	22,000
Deferred transaction costs included in accounts payable and accrued liabilities	0	35,000	46,000	0	—
Amounts accrued for purchases of property and equipment	0	1	571,000	80,000	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Whitehawk Therapeutics, Inc.'s CIK number?

Whitehawk Therapeutics, Inc.'s SEC CIK number is 0001422142 (1422142). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Whitehawk Therapeutics, Inc.'s SEC filings?

All of Whitehawk Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Whitehawk Therapeutics, Inc. last report earnings?

Whitehawk Therapeutics, Inc. (WHWK) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-210615). This is Whitehawk Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Whitehawk Therapeutics, Inc.'s most recent earnings 8-K?

Whitehawk Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-210615. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Whitehawk Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →